Visceral leishmaniasis: immunology and prospects for a vaccine

被引：78
|
作者：
Kaye, P. M. [1 ,2 ]
Aebischer, T. [3 ]
机构：
[1] Univ York, Ctr Immunol & Infect, Hull York Med Sch, York YO10 5YW, N Yorkshire, England
[2] Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England
[3] Robert Koch Inst, D-13353 Berlin, Germany
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2011年 / 17卷 / 10期
关键词：
Immunology; vaccine; visceral leishmaniasis; TRANSMISSION-BLOCKING VACCINE; T-CELLS; CUTANEOUS LEISHMANIASIS; DONOVANI INFECTION; MAJOR INFECTION; MEGLUMINE ANTIMONIATE; CANINE LEISHMANIASIS; ANTIGEN PRESENTATION; PROTECTIVE IMMUNITY; EXPRESSION CLONING;
D O I：
10.1111/j.1469-0691.2011.03610.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
引用
收藏
页码：1462 / 1470
页数：9
相关论文
共 50 条
  • [21] Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
    Duthie, Malcolm S.
    Favila, Michelle
    Hofmeyer, Kimberley A.
    Tutterrow, Yeung L.
    Reed, Steven J.
    Laurance, John D.
    Picone, Alessandro
    Guderian, Jeffrey
    Bailor, H. Remy
    Vallur, Aarthy C.
    Liang, Hong
    Mohamath, Raodoh
    Vergara, Julie
    Howard, Randall F.
    Coler, Rhea N.
    Reed, Steven G.
    VACCINE, 2016, 34 (25) : 2779 - 2786
  • [22] Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development
    Volpedo, Greta
    Pacheco-Fernandez, Thalia
    Bhattacharya, Parna
    Oljuskin, Timur
    Dey, Ranadhir
    Gannavaram, Sreenivas
    Satoskar, Abhay R.
    Nakhasi, Hira L.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [23] Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis
    Ravindran, R
    Ali, N
    CURRENT MOLECULAR MEDICINE, 2004, 4 (06) : 697 - 709
  • [24] The Economic Value of a Visceral Leishmaniasis Vaccine in Bihar State, India
    Lee, Bruce Y.
    Bacon, Kristina M.
    Shah, Mirat
    Kitchen, Sarah Beth
    Connor, Diana L.
    Slayton, Rachel B.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2012, 86 (03): : 417 - 425
  • [25] The FML-vaccine (Leishmune®) against canine visceral leishmaniasis:: A transmission blocking vaccine
    Saraiva, EM
    Barbosa, AD
    Santos, FN
    Borja-Cabrera, GP
    Nico, D
    Souza, LOP
    Mendes-Aguiara, CD
    de Souzaa, EP
    Fampa, P
    Parra, LE
    Menz, I
    Dias, JG
    de Oliveira, SM
    Palatnik-de-Sousa, CB
    VACCINE, 2006, 24 (13) : 2423 - 2431
  • [26] Detection and characterization of leishmania antigens from an American cutaneous leishmaniasis vaccine for diagnosis of visceral leishmaniasis
    Ferreira, WA
    Mayrink, W
    dos Mares-Guia, ML
    Tavares, CAP
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (01) : 35 - 43
  • [27] Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL)
    Borja-Cabrera, G. P.
    Santos, F. B.
    Picillo, E.
    Gravino, A. E.
    Manna, L.
    Palatnik-de-Sousa, C. B.
    VACCINE, 2008,
  • [28] THE EFFECT OF BCG-VACCINE UPON EXPERIMENTAL VISCERAL LEISHMANIASIS IN HAMSTERS
    JARECKIBLACK, JC
    GLASSMAN, AB
    HOLBROOK, TW
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1984, 14 (06): : 464 - 466
  • [29] Impelling TLR9: Road to perspective vaccine for visceral leishmaniasis
    Tiwari, Rohit Kumar
    Gupta, Chhedi Lal
    Bajpai, Preeti
    DRUG DEVELOPMENT RESEARCH, 2022, 83 (02) : 222 - 224
  • [30] Assessment of Vaccine-Induced Immunity Against Canine Visceral Leishmaniasis
    Moreno, Javier
    FRONTIERS IN VETERINARY SCIENCE, 2019, 6
12345